June 4, 2018 Endocrine therapy (ET) alone was noninferior to ET plus chemotherapy for women with estrogen receptor (ER)−positive, HER2-negative, axillary node−negative, early-stage breast cancer (BC) with a midrange score as measured by the Oncotype DX Breast Recurrence Score gene expression assay. The results of the phase III TAILORx trial were announced at a...
Pro zobrazení tohoto obsahu je třeba být přihlášen.